What have we learned? Expert perspectives

Bookmark and Share
Published: 23 Sep 2014
Views: 1998
Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

Dr Hutson (Baylor University Medical Center, Dallas, USA), Prof Oudard (Hôpital Européen Georges Pompidou, Paris, France), Prof Schöffski (University Hospitals Leuven, Leuven, Belgium) and Dr Durán (Associate Director of Clinical Research at START Madrid, Madrid, Spain) reflect upon the points raised during the presentations on mRCC treatment at EIKCS 2014.

Questions such as "What do we need to optimise the use of agents already available for the treatment of mRCC?", "How can we gain a better understanding of which therapy to use and when?", "What can we expect from the investigation of new targets (PDL-1, PD-1) in the future?" and "Will biomarkers and individualised therapy become a reality in mRCC management?" are all considered. In addition, they discuss the use of pazopanib versus sunitinib.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.